Fig. 1From: Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinomaFlowchart of sunitinib dose modifications. (CG – control group, CR – complete remission, DE – dose escalation, DR – dose reduction, LTF – lost to follow-up, N – number of analyzed patients, PD – progressive disease, PR – partial remission, RECIST – Response Evaluation Criteria In Solid Tumors, SD – stable disease, SG – study group)Back to article page